Pratique Neurologique - FMC最新文献

{"title":"Démarche diagnostique générale devant un patient présentant des mouvements anormaux : importance des examens biologiques dans cette stratégie","authors":"A. De Roquemaurel ,&nbsp;D. Gayraud ,&nbsp;M. Fournier ,&nbsp;S. Di Legge","doi":"10.1016/j.praneu.2023.07.003","DOIUrl":"10.1016/j.praneu.2023.07.003","url":null,"abstract":"<div><p>Les mouvements anormaux (MA) représentent un champ majeur de la neurologie moderne. Ils reflètent en général une dysfonction des ganglions de la base, dont les étiologies sont multiples (vasculaires, infectieuses, métaboliques, hématologiques et auto-immunes, iatrogènes et toxiques…). Le premier objectif lors de la démarche clinique va être de définir la typologie prévalente du MA, qui permettra ensuite d’orienter l’enquête étiologique. L’analyse clinique reste donc un élément primordial qui peut bénéficier de l’aide de l’enregistrement vidéo, voire électrophysiologique. Les explorations paracliniques seront ensuite réalisées, avec en priorité l’imagerie cérébrale (imagerie par résonance magnétique). Les examens biologiques vont représenter un élément déterminant dans certains cadres diagnostiques (hématologiques, immunologiques, métaboliques et/ou génétiques par exemple). Notre objectif est de permettre au clinicien de mieux appréhender la place des examens biologiques et leur intérêt dans la démarche diagnostique devant un MA.</p></div><div><p>Movement disorders (MD) represent a major field of modern neurology. MD generally reveals an underlying basal ganglia dysfunction, with various underlying causes (vascular, infectious, metabolic, haematological and auto-immune…). The first step of the clinical approach is to define the phenomenology, which will guide further investigations. This essential task can be helped by video recording and sometimes electrophysiology. Some essential paraclinical investigations will then be ordered, among which brain magnetic resonance imaging (MRI) will play an key role. Besides this and among the plethora of possible tests, blood tests can be decisive in revealing several conditions (including haematological, immunological, metabolic and/or genetic disorders). Our goal is to bring to the general neurology practitioner a better understanding of biological examinations and their value in the process of diagnosing MD.</p></div>","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 3","pages":"Pages 132-149"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45976196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Questionnaires d’autoévaluation : dépistages simples et rapides des troubles sexuels en pratique neurologique. Questionnaire de Plaintes Sexuelles pour les Femmes (QPS-F)/Questionnaire de Plaintes Sexuelles pour les Hommes (QPS-H)","authors":"S. Bresch, R. Colamarino","doi":"10.1016/j.praneu.2023.07.005","DOIUrl":"https://doi.org/10.1016/j.praneu.2023.07.005","url":null,"abstract":"","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49240045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hommage au professeur Jean Cambier (1925–2022)","authors":"B. Lechevalier,&nbsp;M. Masson,&nbsp;P. Verstichel,&nbsp;F. Viader","doi":"10.1016/j.praneu.2023.06.001","DOIUrl":"https://doi.org/10.1016/j.praneu.2023.06.001","url":null,"abstract":"","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 71-73"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49702047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migraine, nouveautés thérapeutiques et recommandations : comment j’adapte la prise en charge au quotidien ?","authors":"X. Moisset","doi":"10.1016/j.praneu.2023.04.001","DOIUrl":"10.1016/j.praneu.2023.04.001","url":null,"abstract":"<div><p>Les nouveautés thérapeutiques et les recommandations sont rappelées. L’accent est tout d’abord mis sur l’évaluation du patient migraineux. L’objectif est de reprendre les points majeurs des recommandations et de préciser quelques éléments pratiques concernant l’utilisation des traitements de premier choix, mais aussi de la toxine botulinique et des anticorps monoclonaux ciblant la voie du CGRP. Deux vignettes sont exposées et les prises en charge sont alors adaptées.</p></div><div><p>New therapies and recommendations are reviewed. The emphasis is first placed on an evaluation of the migraine patient. The aim is to review the major points of the guidelines and to outline some practical elements concerning the use of first choice treatments, as well as botulinum toxin and monoclonal antibodies targeting the CGRP pathway. Two vignettes are presented and the management is then adapted.</p></div>","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 84-89"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45165320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurosciences : embarquement pour les horizons imaginaires et les nouveaux continents du savoir !","authors":"C. Thomas-Anterion","doi":"10.1016/j.praneu.2023.04.005","DOIUrl":"10.1016/j.praneu.2023.04.005","url":null,"abstract":"","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Page 129"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41420445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Le malade était blanc comme un linge","authors":"A. Nguyen ,&nbsp;H. Oesterle ,&nbsp;A. Camoreyt ,&nbsp;F. Vuillemet ,&nbsp;F. Sellal","doi":"10.1016/j.praneu.2023.04.009","DOIUrl":"https://doi.org/10.1016/j.praneu.2023.04.009","url":null,"abstract":"","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 121-123"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49705229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fiches pratiques thérapeutiques pour la prise en charge des patients atteints de sclérose en plaques","authors":"H. Zéphir ,&nbsp;F. Durand-Dubief ,&nbsp;E. Le Page ,&nbsp;sous l’égide de la Société Francophone de la Sclérose en Plaques (SFSEP)","doi":"10.1016/j.praneu.2023.02.003","DOIUrl":"10.1016/j.praneu.2023.02.003","url":null,"abstract":"<div><p>Plus d’une douzaine de spécialités thérapeutiques sont proposées aujourd’hui dans la prise en charge des patients atteints de sclérose en plaques (SEP). Il s’agit d’immunothérapies immuno-modulatrices ou immuno-suppressives, de classes différentes, qui peuvent se succéder tout au long de la maladie. Il est donc nécessaire de composer avec les risques spécifiques de chacun des traitements, les risques liés aux switchs thérapeutiques, les risques infectieux, les risques de tératogénicité et/ou réactivation de la maladie à l’arrêt du traitement en cas de projet de grossesse, tout en ayant la réactivité thérapeutique anti-inflammatoire suffisante pour préserver le capital neurologique. Face au patient ayant une SEP, le neurologue doit appréhender ces différents paramètres qui guideront la décision thérapeutique. Sous l’égide de la SF-SEP, nous proposons des fiches pratiques thérapeutiques, compilant les données des caractéristiques des différents traitements, les recommandations publiées par la SF-SEP (SEP et vaccination, grossesse, risque infectieux), et ses propositions en cas de switch. Nous soulignons l’importance des discussions des situations individuelles complexes à réaliser lors de réunions de concertation au sein des centres de ressources et compétence SEP pour une meilleure stratégie de prise en charge.</p></div><div><p>Numerous immunotherapies are currently proposed for the treatment of patients with multiple sclerosis (MS). These are immunomodulative or immunosuppressive therapies, of different classes, which are planned to be used for the long term. Therefore neurologists must anticipate the specific risks of each treatment, the risk related to therapeutic switch, the risk of infection overtime, of teratogenicity and/or disease reactivation when stopping treatment in case of pregnancy plan while a therapeutic anti-inflammatory reactivity is important for the best prevention of chronical neurological damage. Faced with a patient with MS, the neurologist's mission is to take into account the different parameters that will guide the therapeutic decision (initiation or switch) and the required monitoring. We propose practical treatment sheets, combining characteristics of the different treatments, the recommendations of the French MS Society (Société francophone de la sclérose en plaques SF-SEP) (MS and vaccinations, infections, pregnancy), and their propositions when switching. We emphasize the importance of discussing complex individual situations with expert MS centers for the best management strategy.</p></div>","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 98-107"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48882376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discrétion, discrétion : est-ce que j’ai une gueule de discrétion ?","authors":"C. Thomas-Anterion","doi":"10.1016/j.praneu.2023.04.003","DOIUrl":"10.1016/j.praneu.2023.04.003","url":null,"abstract":"","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 127-128"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44465982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Un traitement salé","authors":"M. Dhoisne,&nbsp;L. Sermet,&nbsp;L. Defebvre,&nbsp;T. Ollivier","doi":"10.1016/j.praneu.2023.04.008","DOIUrl":"10.1016/j.praneu.2023.04.008","url":null,"abstract":"","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 118-120"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41649276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilisation pratique du pérampanel dans les crises d’épilepsie de l’enfant et de l’adolescent","authors":"S. Auvin ,&nbsp;R. Nabbout ,&nbsp;C. Gonin ,&nbsp;R.P. Garay ,&nbsp;R. Bournane ,&nbsp;A. Arzimanoglou","doi":"10.1016/j.praneu.2022.12.001","DOIUrl":"10.1016/j.praneu.2022.12.001","url":null,"abstract":"<div><p>Le pérampanel est le premier antagoniste des récepteurs AMPA autorisé en Europe pour être utilisé en association. Il est à ce jour indiqué dans le traitement des : (i) crises d’épilepsie focales avec ou sans généralisation secondaire chez les patients âgés de 4 ans et plus et des (ii) crises généralisées tonicocloniques primaires (GTCP) chez les patients âgés de 7 ans et plus atteints d’épilepsie généralisée idiopathique (EGI). Depuis son autorisation de mise sur le marché en France (juillet 2013) de nouvelles données ont été publiées notamment chez l’enfant et l’adolescent. Nous avons revu ces données, afin de proposer des bonnes pratiques d’utilisation du pérampanel dans la population pédiatrique.</p></div><div><p>Perampanel is the first AMPA receptor antagonist approved in Europe for use as add-on therapy. It is currently indicated for the treatment of: (i) partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 years of age and older and (ii) primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age and older with idiopathic generalised epilepsy (IGE). After its marketing authorization in France (July 2013), new data have been published, particularly in children and adolescents. We have reviewed these data, in order to propose good practices for the use of perampanel in the pediatric population.</p></div>","PeriodicalId":53613,"journal":{"name":"Pratique Neurologique - FMC","volume":"14 2","pages":"Pages 74-83"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42212360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}